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ing units (n 2) were diluted at least 4 fold to a ﬁnal volume of 400
mls. The median infused TNC was 2.13 x 107/kg with a TNC
recovery of 85% (range 50-105%) and a median trypan blue via-
bility of 89% (range 59-95%). While 6 patients had hypertension,
3 nausea and 1 chest tightness requiring intravenous therapy, no
patient suffered any severe adverse events associated with infusion.
The cumulative incidence of sustained donor neutrophil engraft-
ment was 100% in recipients of ablative regimens at a median of 26
days (range 14-33), and 89% in non-myeloablative recipients with
neutrophil recovery occurring at a median of 16 days (range 7-36).
The cumulative incidence of grades II-IV acute GVHD was 42%
at 100 days with no cases of grade IV acute GVHD, and 20% of
patients have chronic GVHD to date. In summary, we conclude
that this thaw technique is a valid alternative to UCB wash in adults
and larger children with cell dose yield and engraftment that
compare favorably to a traditional wash. This technique is faster,
more efﬁcient, reduces unit manipulation, speeds the time to pa-
tient infusion, and reduces the potential for loss of cells and may
therefore be the thaw technique of choice for adult UCBT.
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NONMYELOABLATIVE STEM CELL TRANSPLANTATION
Richard Champlin, M.D. MD Anderson Cancer Center
High dose myeloablative therapy with allogeneic hematopoietic
transplantation is an effective, yet risky treatment for hematologic
malignancies. There is a high risk of treatment related complica-
tions, ranging from 10 to 50% depending on histocompatibility,
age comorbidities and disease factors. The initial concept of allo-
geneic transplantation for treatment of cancer was to use the
transplant for supportive care, as a means to restore hematopoiesis
after myeloablative doses of chemotherapy and/or total body radi-
ation. The therapeutic beneﬁt of allogeneic marrow transplanta-
tion for many diagnoses is largely related to an associated immune-
mediated graft-vs.-malignancy effect. This realization has recently
led to development of less toxic, nonmyeloablative preparative
regimens to achieve engraftment and allow development of graft-
vs.-malignancy effects as a primary form of therapy. Engraftment is
favored by a high CD34 cell dose and histocompatiblity between
donor and recipient. More intensive immunosuppression is re-
quired to prevent rejection with greater genetic disparity. For cord
blood transplants, the preparative regimen must be sufﬁciently
immunosuppressive to prevent rejection of the cord blood graft,
involving a low cell dose and usually multiple HLA mismatches.
For nonmalignant disorders, it is not necessary to ablate diseased
tissues; it is only necessary to achieve mixed chimerism to provide
a source of normal hematopoietic cells. Results of nonablative stem
transplants will be reviewed for each hematologic malignancy. In
many diagnoses, it still appears necessary to induce marked cytore-
duction by the preparative regimen to achieve optimal results.
Strategies to augment graft-vs-malignancy immune effects are be-
ing studied to reduce the risk of disease relapse. Novel strategies
are under evaluation for separation of graft-vs-malignancy from
GVHD. Overall this strategy has been successful in reducing the
risks of treatment related mortality and making it a potentially
curative treatment option to older patients and those with comor-
bidities who where previously not eligible for allogeneic stem cell
transplantation.
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Over the last 20 years, umbilical cord blood(UCB) has become an
increasingly used source of hematopoeitic stem cells for transplan-
tation. For pediatric patients, UCB is now routinely utilized as a
source of stem cells. However, the median age of presentation of
most hematologic malignancies is in the 5th and 6th decades of life,
a time when other co-morbidities are more likely. Also, patients are
frequently referred to transplantation after extensive prior therapy,
including prior autologous transplantation. Nonmyeloablative
transplantation is particularly suitable for older patients and those
with other signiﬁcant clinical problems. The nonmyeloablative
conditioning regimens utilize drugs that are potently immunosup-
pressive with less toxicity and shortened periods of neutropenia.
The utilization of UCB as a source of stem cells for non myeloa-
blative transplantation was based on the hypothesis that despite less
alloreactivity, UCB would have enough T cells to mediate engraft-
ment. Several groups have now reported results with nonmyeloa-
blative UCB transplantation. The conditioning regimen has varied
signiﬁcantly; however, most institutions have included ﬂudarabine
and TBI. Among the series reported the median age of patients at
transplantation has ranged from 47 to 59 years, and the median
time to neutrophil recovery ranged between 12 and 21 days, with
an incidence of graft failure between 13% to 16%. The variation
on the time to neutrophil recovery largely reﬂects differences in
the intensity of the conditioning regimen. Despite the fact that the
best nonmyeloablative conditioning regimen for UCB transplan-
tation is not yet established, a recent study by Rocha et al. suggests
the combination of cyclophosphamide, ﬂudarabine and total body
irradiation may be superior to other regimens, with an incidence of
sustained donor engraftment of approximately 90%, as compared
to 65% with other regimens. The reported incidences of acute
graft-versus-host disease have ranged between 21% and 63%, and
chronic graft-versus-host disease 12% and 50%. Treatment related
mortality has been remarkably low, ranging from 18% to 27%.
Overall survival has been 33% to 44%. The University of Minne-
sota has the largest single center experience with nonmyeloabla-
tive UCB transplantation. The Minneapolis conditioning regi-
men consists of cyclophosphamide 50mg/kg, ﬂudarabine
200mg/m2 and a single dose of TBI 200cGy. The posttrans-
plantation immunosuppression is cyclosporine A and mycophe-
nolate mofetil. For patients who have not received intensive
chemotherapy in the 3 months prior to transplantation, anti-
thymocyte globulin was added to the conditioing regimen. If a
single unit is not large enough to be used as a graft, patients are
eligible to receive two partially HLA matched UCB units. UCB
unit grafts are at least 4/6 HLA matched to the recipent (HLA-A
and B at the antigen level, and DRBI at the allele level). In the
case of double unit grafts, units are at least 4/6 HLA matched to
the recipient and to each other, not necessarily at the same loci.
The median infused nucleated cell dose is 3.3  107/kg recip-
ients of one unit, compared to 3.7  107/kg for recipients of two
units. With 161 patients, primary neutrophil recovery is ob-
served in 94% with sustained donor engraftment in 87%. There
is no signiﬁcant difference between recipients of one or two
UCB units. Treatment related mortality is 25% at 3 years. The
incidence of Grade II-graft-versus-host disease is 54% and
grade III-IV 18%. Progression-free survival is 38% at 5 years
with a trend towards better progression-free survival for recip-
ients of 2 UCB units. Overall survival is 45% at 5 years, with no
signiﬁcant difference for recipients of one or two UCB units. In
multivariate analysis, disease’s status at transplantation and the
presence of clinical high-risk features were the two factors
correlated with higher risk of treatment related mortality,
poorer event-free survival and overall survival. In conclusion, a
growing body of evidence suggests that UCB is a safe and
efﬁcacious source of stem cells in the setting of myeloablative
transplantation. Patients who need non myeloabalative trans-
plant and who do not have a suitable sibling or unrelated donor
should be considered for UCB transplantation. Larger numbers
of patients will help further determine the role of UCB trans-
plantation in older patients and those with pre-exising co-
morbidities.
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